Cardiac consequences of aldosterone excess in human hypertension.
Rossi
Gian Paolo
GP
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology / Q000627:therapeutic use; D000450:Aldosterone / Q000502:physiology; D000804:Angiotensin II / Q000502:physiology; D001794:Blood Pressure / Q000187:drug effects; D002121:Calcium Channel Blockers / Q000494:pharmacology / Q000627:therapeutic use; D002319:Cardiovascular System / Q000503:physiopathology*; D002986:Clinical Trials as Topic; D004719:Endomyocardial Fibrosis / Q000473:pathology / Q000503:physiopathology; D006801:Humans; D006929:Hyperaldosteronism / Q000150:complications / Q000473:pathology / Q000503:physiopathology*; D006973:Hypertension / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology*; D006978:Hypertension, Renovascular / Q000150:complications / Q000175:diagnosis / Q000503:physiopathology*; D017379:Hypertrophy, Left Ventricular / Q000209:etiology / Q000473:pathology / Q000503:physiopathology*; D008137:Longitudinal Studies; D012084:Renin-Angiotensin System / Q000502:physiology; D012189:Retrospective Studies
D000319:Adrenergic beta-Antagonists; D002121:Calcium Channel Blockers; D000804:Angiotensin II; D000450:Aldosterone